Latest Conference Articles

With stringent criteria, randomized controlled trials are the cornerstone of cancer intervention research, but the result is they do not represent the majority of patients, which leads to a gap between the efficacy seen in trials and the effectiveness in the real-world setting.

Patients with alopecia areata found effective treatment with baricitinib, which had long-term efficacy and positive results.

Kevin Kalinsky, MD, MS, of Glenn Family Breast Center, gives insight into the real-world data supporting the use of sacituzumab govitecan-hziy in the treatment of triple-negative breast cancer (TNBC).

A panel hosted at Fall Clinical Dermatology 2023 highlighted how dermatologists can help to address acne and psoriasis in their patients.

Max Parmar, professor of medical statistics and epidemiology at University College London, unpacks what clinicians and patients can gain from the application of multiarm multistage (MAMS) trials.

Atopic dermatitis, psoriasis, and hidradenitis suppurativa (HS) can present differently in diverse patients, potentially leading to delayed diagnosis and therefore delayed treatment, explained James Song, MD, director of clinical research and associate chief medical officer at Frontier Dermatology.

Both adolescents and adults saw improvements with the use of ruxolitinib or povorcitinib to treat their nonsegmental vitiligo.

The FDA approval of topical ruxolitinib 1.5% cream changed the game for vitiligo treatment in both adult and pediatric patients, said Raj Chovatiya, MD, PhD, assistant professor of dermatology at Northwestern University's Feinberg School of Medicine.

Prerakkumar Parikh, PharmD, of Megallen Rx Management/Prime Therapeutics, detailed the impact of formulary placement of biosimilars on cost burden along with how stakeholders can work with pharmacy benefit managers to promote biosimilar use.

“There are things more important than our discomfort, and there are things that are more important than even our fear—inclusion is more important,” said Erica Marsh, MD, MSCI. “Our care of our patients and loved ones is more important, and our existence tomorrow has to be more important than our fears today.”

A panel held at Fall Clinical Dermatology 2023 emphasized the role of Janus kinase (JAK) inhibitors in several skin conditions and highlighted new therapies in the space.

Peter A. Lio, MD, clinical assistant professor of dermatology and pediatrics at Northwestern University's Feinberg School of Medicine, addresses how dermatologists need to focus on patient needs when determining the best use of new biologics in moderate to severe atopic dermatitis.

Saira Jan, PharmD, MS, of Horizon Blue Cross Blue Shield of New Jersey, discussed the primary findings of their collaborative pilot program with Rutgers Cancer Institute of New Jersey and RWJ Barnabas Health, focusing on patient and provider experiences.

Posters presented at the American Society for Reproductive Medicine 2023 Scientific Congress & Expo highlighted trends in fertility care amid the turbulent landscape following the Dobbs decision.

Results of the monarchE study showed patients with hormone receptor–positive (HR+), HER2-negative (HER2–) high-risk, early breast cancer had greater benefit after 5 years when receiving adjuvant abemaciclib plus endocrine therapy vs endocrine therapy alone.

Posters presented at the American Society for Reproductive Medicine (ASRM) 2023 Scientific Congress & Expo addressed psychosocial symptoms and burdens faced by both embryologists and women of color with uterine fibroids.

Janus kinase (JAK) inhibitors are not only efficacious in terms of skin disease improvement, but also in terms of itch management, explained Mona Shahriari, MD, assistant clinical professor of dermatology at Yale University and associate director of clinical trials at Central Connecticut Dermatology.

Valerie Montgomery Rice, MD, FACOG, a distinguished infertility specialist, highlights the pivotal role of cultural humility, diversity, acknowledgment of historical injustices, and collective action in addressing disparities and fostering equitable access to health care.

Operational forecasting for patients who are eligible for gene therapies will be crucial for addressing the accessibility and affordability challenges with these agents, especially as more gene therapies are expected to enter the market in the next few years.

Chelsee Jensen, PharmD, BCPS, of Mayo Clinic, commented on the recent FDA biosimilar approvals and what they mean for the industry's future, as well as how to ensure biosimilars are accessible to all patients.

Anita Allen, PhD, professor of law and philosophy, University of Pennsylvania, discusses the impact of abortion regulations in different parts of the world on women's reproductive access and rights, as well as the repercussions of the Dobbs decision that overturned Roe v Wade.

The landscape for biologics to treat patients with psoriasis looks excellent, said April Armstrong, MD, MPH, professor and chief of dermatology at UCLA.

During a session at AMCP Nexus, panelists provided a historical overview on the 340B drug discount program, highlighting the intentions of the plan and the research gaps leading to misconceptions about the program and whether it’s working to lower costs for patients.

Speakers at AMCP Nexus 2023 reviewed the major changes resulting from the Inflation Reduction Act (IRA) that impacted Medicare in 2023 and previewed the new provisions being implemented in the coming years.

Kristen Whelchel, PharmD, CSP, of Vanderbilt University Medical Center, details what services medically integrated dispensing (MID) specialty pharmacies provide.

In the aftermath of the Dobbs v Jackson Women’s Health Organization ruling, Anita Allen, PhD, highlights the challenges to abortion rights in the United States, emphasizing disparities faced by marginalized communities, outlining threats to reproductive health care, and calling for collective action and advocacy to defend constitutional privacy and uphold the dignity of all individuals.

Pawel Sobczuk, MD, PhD, of the Maria Sklodowska-Curie National Research Institute of Oncology in Warsaw, Poland, previews the upcoming ESMO Congress 2023 in Madrid, Spain.

Two posters presented at the American Society for Reproductive Medicine 2023 Scientific Congress & Expo address racial and socioeconomic factors that impact fertility and birth outcomes.